Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice

  • Cancer Chemother Pharmacol. 2001 Nov;48(5):413-6. doi: 10.1007/s002800100358.
H S Friedman  1 ,  S T Keir ,  P J Houghton ,  A A Lawless ,  D D Bigner ,  S J Waters
Affiliations
  • 1. Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
PMID: 11761460 DOI: 10.1007/s002800100358
Abstract

Purpose: This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice.

Methods: Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10% lethal dose with responses compared to tumor-bearing mice treated with drug vehicle.

Results: Irofulven was active against all tumor lines tested with growth delays ranging from 5.6 to 81.6 days (all values statistically significant, P < or = 0.001). Irofulven also produced a statistically significant (P < or = 0.001) increase in the median survival of mice bearing D-456 intracranial xenografts with a 162% increase in median survival.

Conclusions: Irofulven is active in a spectrum of human glioblastoma multiforme-derived xenografts and evaluation in patients with this neoplasm is warranted.

Products